E.p.dis Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: E.p.dis Pharmaceutical Import Records from India — 5 Products, $5.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

E.p.dis — Pharmaceutical Importer Profile (2026) | 5 Products, $5.0M Trade | TransData Nexus

E.p.dis

Pharmaceutical Importer · France · Advanced Antibiotics Focus · $5.0M Total Trade · DGFT Verified

E.p.dis is a pharmaceutical importer based in France with a total trade value of $5.0M across 5 products in 5 therapeutic categories. Based on 189 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. E.p.dis sources from 9 verified Indian suppliers, with Micro Labs Limited accounting for 82.0% of imports.

E.p.dis — Import Portfolio & Supplier Network

E.p.dis import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to E.p.dis?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Micro Labs Limited	$22.9M	1,451	82.0%
Emcure Pharmaceuticals Limited	$2.8M	229	10.1%
Indus Life Sciences Private Limited	$852.5K

What Formulations Does E.p.dis Import?

Formulation	Value	Ships
Pharmaceuticals products - ( finished	$1.3M	95
Aminopep forte liquid 200ML	$250.0K	5
Pharmaceuticals article / ods / product / item - finished	$249.5K	20
Nugel o suspension 200ML	$235.1K	8
Ipeprazole 20MG cpr bt	$232.5K	6
Avas 20 MG ( (atorvastatin 20MG tablets)) ( 3x10s ) ( qty- 29545.000	$147.7K	3
Celebid 200 ( (celecoxib 200MG capsules)) ( 3x10s ) ( qty- 24696.000	$141.4K	3
Pharmaceuticals products - ( finished product) orofer 50 MG syrup 150 ML bt ( iron [iii] hydroxide polymaltose complex	$141.3K	12
Ornilox ( (ofloxacin + ornidazole	$130.5K	3
Gramocef-o-100 dry syrup ( (cefixime	$128.4K	4
Pharmaceuticals products -(finis. product) orofer 50 MG syrup 150 ML bt (iron [iii] hydroxide polymaltose complex	$125.7K	3
Bactoclav 1000 ( (amoxicillin 875MG &	$115.9K	3
Celebid 200 ( (celecoxib 200MG capsules)	$113.6K	4
Avas 20 ( (atorvastatin 20MG tablets) )	$112.8K	3
Allercet 10 ( (cetirizine	$108.3K	3

E.p.dis imports 1,360 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ornidazole	Advanced Antibiotics	$1.9M	52	7.4%	2
2	Celecoxib	Analgesics & Antipyretics	$1.6M	36	1.2%	11
3	Ketoconazole	Antifungals	$686.8K	29	1.7%	12
4	Levofloxacin	Antibiotics	$602.2K	44	0.8%	17
5	Torsemide	Diuretics	$247.5K	28	0.8%	13

E.p.dis imports 5 pharmaceutical products across 5 categories into France totaling $5.0M.

E.p.dis — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

E.p.dis is a French pharmaceutical company specializing in the wholesale distribution of pharmaceutical products. Established on March 8, 2000, and headquartered at 8 Avenue Paul Delorme, 76120 Le Grand-Quevilly, France, E.p.dis operates as a Société Anonyme (SA), a common corporate structure in France. (entreprises.lefigaro.fr) The company employs approximately three individuals at this location. (allbiz.fr)

E.p.dis functions as a pre-wholesale export distributor, primarily managing exports to around 50 destinations in Sub-Saharan Africa for pharmaceutical companies. This role involves overseeing the logistics and distribution of pharmaceutical products, ensuring compliance with regulatory standards, and maintaining the integrity of the supply chain. The company's operations are duly registered with the Agence Nationale de Sécurité des Médicaments (ANSM), the French regulatory body responsible for the safety of health products.

2Distribution Network

E.p.dis operates a 24,000 m² logistics hub located in Val de Reuil, France. This facility serves as the central point for managing exports to approximately 50 destinations in Sub-Saharan Africa. The company's distribution network is designed to ensure the efficient and secure delivery of pharmaceutical products, adhering to the highest standards of pharmaceutical logistics, including the maintenance of the cold chain to preserve product efficacy.

3Industry Role

In France's pharmaceutical supply chain, E.p.dis operates as a pre-wholesale export distributor. This role involves importing pharmaceutical products from international manufacturers and managing their distribution to various markets, particularly in Sub-Saharan Africa. By handling the logistics and regulatory compliance aspects, E.p.dis facilitates the entry of pharmaceutical products into these markets, ensuring that they meet the necessary standards and reach the intended destinations efficiently.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — E.p.dis

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

E.p.dis's sourcing strategy exhibits a high degree of concentration, with a significant portion of its imports originating from a single supplier, MICRO LABS LIMITED. This supplier accounts for 82% of the total import value, indicating a strong dependency on this source. Such concentration can pose risks, including potential supply chain disruptions if issues arise with the primary supplier. However, the stability of the relationship, as evidenced by the consistent volume of shipments, suggests a strategic choice to leverage the supplier's capabilities and reliability. The remaining 18% of imports are distributed among eight other suppliers, indicating a diversified sourcing approach to mitigate potential risks.

2Supply Chain Resilience

E.p.dis's supply chain resilience is bolstered by its diversified supplier base, despite the predominant reliance on MICRO LABS LIMITED. The company imports a total of 1,360 unique pharmaceutical formulations, reflecting a broad product portfolio that can help mitigate risks associated with supply chain disruptions. Additionally, E.p.dis's logistics hub in Val de Reuil is equipped to handle complex distribution requirements, including the maintenance of the cold chain, which is crucial for the stability and efficacy of pharmaceutical products. The company's registration with the ANSM underscores its commitment to regulatory compliance, further enhancing the resilience of its supply chain.

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the Agence Nationale de Sécurité des Médicaments (ANSM) is the primary regulatory authority overseeing the safety and efficacy of health products, including pharmaceuticals. The ANSM is responsible for granting marketing authorizations, monitoring the safety of medicines, and ensuring compliance with European Union regulations. For Indian pharmaceutical companies seeking to export to France, obtaining a marketing authorization from the ANSM is a critical step. This process involves submitting comprehensive documentation, including clinical trial data, manufacturing details, and quality control measures, to demonstrate that the product meets the required standards. The ANSM evaluates these submissions to ensure that imported pharmaceuticals are safe for the French market.

2Import Licensing & GMP

Import licensing requirements in France are stringent, necessitating that pharmaceutical products comply with Good Manufacturing Practice (GMP) standards recognized by the European Union. Indian pharmaceutical manufacturers must ensure that their facilities are certified by an authority whose GMP standards are accepted by the EU, such as the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, Indian exporters must obtain a wholesale distribution authorization to legally distribute pharmaceutical products within France. This authorization requires adherence to specific storage, handling, and distribution protocols to maintain product integrity and comply with French regulations.

E.p.dis — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

E.p.dis's product strategy focuses on importing pharmaceutical formulations across five therapeutic categories, with a significant emphasis on Advanced Antibiotics (37.9%), Analgesics & Antipyretics (31.6%), and Antifungals (13.6%). This focus aligns with the therapeutic needs of the Sub-Saharan African markets, where infectious diseases and pain management are prevalent concerns. The top five imported products—Ornidazole, Celecoxib, Ketoconazole, Levofloxacin, and Torsemide—are indicative of the company's strategic alignment with these therapeutic areas. By concentrating on these categories, E.p.dis aims to address critical health challenges in the regions it serves.

2Sourcing Profile

E.p.dis's sourcing strategy is heavily reliant on Indian pharmaceutical manufacturers, with MICRO LABS LIMITED being the predominant supplier. This reliance suggests that E.p.dis values the cost-effectiveness and quality of Indian generics. The company's import portfolio includes a diverse range of formulations, indicating a preference for suppliers capable of providing a broad spectrum of products. For Indian exporters, this presents an opportunity to strengthen partnerships with E.p.dis by offering a wide array of high-quality pharmaceutical formulations that meet the company's standards and regulatory requirements.

3Market Positioning

Seller's Guide — How to Become a Supplier to E.p.dis

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter E.p.dis's supply chain. The company's diversified sourcing approach, as evidenced by its engagement with multiple suppliers, indicates openness to establishing new partnerships. Indian exporters can capitalize on this by offering high-quality pharmaceutical formulations that meet E.p.dis's standards and regulatory requirements. By demonstrating reliability, compliance, and the ability to meet specific therapeutic needs, Indian suppliers can position themselves as valuable partners to E.p.dis.

2Requirements & Qualifications

Indian pharmaceutical exporters seeking to supply E.p.dis must ensure that their products comply with EU-recognized GMP standards, such as those set by the WHO or PIC/S. Obtaining a marketing authorization from the ANSM is essential, which involves submitting comprehensive documentation to demonstrate product safety and efficacy. Additionally, exporters must adhere to French labeling requirements, including providing information in French and meeting serialization mandates. Ensuring compliance with these standards is crucial for gaining access to the French market through E.p.dis.

TransData Nexus Research · Industry procurement practices

Frequently Asked Questions — E.p.dis

What products does E.p.dis import from India?

E.p.dis imports 5 pharmaceutical products across 5 categories. Top imports: Ornidazole ($1.9M), Celecoxib ($1.6M), Ketoconazole ($686.8K), Levofloxacin ($602.2K), Torsemide ($247.5K).

Who supplies pharmaceuticals to E.p.dis from India?

E.p.dis sources from 9 verified Indian suppliers. The primary supplier is Micro Labs Limited (82.0% of imports, $22.9M).

What is E.p.dis's total pharmaceutical import value?

E.p.dis's total pharmaceutical import value from India is $5.0M, based on 189 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does E.p.dis focus on?

E.p.dis imports across 5 categories. The largest: Advanced Antibiotics (37.9%), Analgesics & Antipyretics (31.6%), Antifungals (13.6%).

Get Full E.p.dis Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.